ClinicalTrials.gg
CompletedNCT04015180FIREFLEYE nextUpdated Oct 10, 2025

Extension Study to Evaluate the Long-term Outcomes of Subjects in Study 20090

A Phase 3 interventional study of Eylea (Aflibercept, BAY86-5321) and Laser photocoagulation in Retinopathy of Prematurity (ROP), sponsored by Bayer. Completed at 55 sites in 24 countries. Open to participants aged Up to 13 Months. Per ClinicalTrials.gov, last updated 2025-10-10.

Sponsored by Bayer · Phase 3, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
100
Allocation
Non-randomized
Ages
Up to 13 Months
Sex
All
01

Study summary

This is a follow-up study to evaluate the long term outcome of babies treated in the FIREFLEYE study.

02

Conditions studied

  • Retinopathy of Prematurity (ROP)
03

In context

Retinopathy of Prematurity

169 studies on the registry are indexed under Retinopathy of Prematurity; 27 are open to participants now.

This study's enrollment of 100 is above the median of 82 across 102 interventional studies indexed under Retinopathy of Prematurity.

Browse Retinopathy of Prematurity studies →

Lead sponsor

Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.

Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 13 Months
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject was treated in Study 20090
  • Age less than 13 months of chronological age
  • Signed from parent(s)/legally authorized representative(s), which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol

Exclusion criteria

Exclusion Criteria:

- Subject has a condition preventing participation in the study, or performance of study procedures.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    Aflibercept arm

    No study treatment will be administered. The treatments to be evaluated in this study were administered in Study 20090.

    Drug: Eylea (Aflibercept, BAY86-5321)

  • Active comparator
    Laser photocoagulation arm

    No study treatment will be administered. The treatments to be evaluated in this study were administered in Study 20090.

    Procedure: Laser photocoagulation

Interventions

  • Treatment administered in 20090. Solution in a sterile glass vial, Dose A, IVT injection.

  • ProcedureLaser photocoagulation

    Treatment administered in 20090. Transpupillary conventional laser ablative therapy

06

What researchers measure

Primary outcomes

  1. Binocular best-corrected visual acuity in Snellen equivalent

    Time frame: At 5 years of age.

  2. Proportion of subjects with ocular AEs and SAEs

    AE: adverse event SAE: serious adverse event

    Time frame: Up to 5 years of age.

  3. Proportion of subjects with systemic AEs and SAEs

    Time frame: Up to 5 years of age.

Secondary outcomes

  1. Proportion of subjects developing unfavorable ocular structural outcome

    Unfavorable ocular structural outcome include: retinal detachment, macular dragging, macular fold, retrolental opacity

    Time frame: At 1,3 and 5 years of age.

  2. Proportion of subjects with absence of active ROP and unfavorable structural outcomes

    Time frame: At 1 year of age.

  3. Best-corrected visual acuity in each eye

    Time frame: At 3 and 5 years of age.

  4. Refractive spherical equivalent in each eye

    Time frame: At 3 and 5 years of age

  5. Neurodevelopmental outcomes using BSID-III

    BSID-III: The Bayley Scales of Infant and Toddler Development, Third Edition (BSID-III) is a standard series of tests that will assess the development of children in 3 areas: cognition, language, and motor skills. It is recommended to be assessed at screening, 1 year and 2 years of age. The assessment at 2 years of age is mandatory.

    Time frame: At 2 years of age

  6. Neurodevelopmental outcomes using WPPSI-IV

    WPPSI-IV: The Wechsler Preschool and Primary Scale of Intelligence, Fourth Edition is designed to assess development of older children and is recommended to be performed at 3, 4 and 5 years of age. The assessment at 5 years of age is mandatory. In cases where the WPSSI-IV cannot be used, the Differential Ability Scales II (DAS-II) may be used as an alternative.

    Time frame: At 5 years of age

  7. Neurodevelopmental outcomes using VABS-II

    VABS-II: Vineland Adaptive Behavior Scales, Second Edition Expanded Interview will be included, which includes 4 areas: Communication, Daily Living skills, Socialization and Motor Skills. It is recommended to be assessed at 2, 3, 4 and 5 years of age. The assessments at 2 years and 5 years of age are mandatory.

    Time frame: At 2 and 5 years of age

  8. Proportion of subjects with recurrence of ROP

    Time frame: At 3 and 5 years of age.

  9. Proportion of subjects requiring treatment for ROP

    Time frame: Up to 5 years of age.

  10. Proportion of subjects requiring ophthalmological treatment

    Time frame: Up to 5 years of age.

07

Study locations

55 sites
  • Hospital Público Descentralizado "Dr. Guillermo Rawson"
    San Juan, 5400, Argentina
  • AZ Sint Jan Brugge - Ophthalmology
    Bruges, 8000, Belgium
  • Hospital das Clínicas de Botucatu - UNESP Botucatu
    Botucatu, São Paulo TBC, Brazil
  • Unifesp/Epm
    São Paulo, 04024-002, Brazil
  • UMHAT Sveti Georgi
    Plovdiv, 4002, Bulgaria
  • Acibadem City Clinic Multiprofile Hospital for Active Treatm
    Sofia, 1407, Bulgaria
  • Spec. Hospital of Ophthalm. for Active Treatment Visus
    Sofia, 1619, Bulgaria
  • Spec. Hosp. of Ophthalm. Disease for Active Treatment Varna
    Varna, 9000, Bulgaria
  • Fakultní nemocnice Ostrava
    Ostrava, 708 52, Czechia
  • Všeobecná fakultní nemocnice v Praze
    Prague, 12808, Czechia
  • Children's Hospital of Athens P&A Kyriakou - Pediatric Nephrology Department
    Athens, MISSING, Greece
  • General Hospital Of Thessaloniki Papageorgiou-2nd Ophthalmology Clinic
    Efkarpia, 564 29, Greece
  • University General Hospital of Ioannina
    Ioannina, 45500, Greece
  • Eszak-Kozep-budai Centrum, Uj Szent Janos Korhaz és Szakrendelo
    Budapest, H-1125, Hungary
  • Kaplan Medical Center
    Rehovot, 7610001, Israel
  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS - UOC Oculistica
    Rome, Lazio 00136, Italy
  • Ospedale Pediatrico Bambino Gesù - Oculistica
    Rome, Lazio 00165, Italy
  • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico - Oculistica
    Milan, Lombardy 20122, Italy
  • A.O. di Perugia_Hospital Santa Maria della Misericordia - S.C. Oculistica
    Perugia, Umbria 06129, Italy
  • Hospital of the University of Occupational and Environmental Health, Japan
    Kitakyushu, Fukuoka 807-8556, Japan
  • Kurume University Hospital
    Kurume, Fukuoka 830-0011, Japan
  • Okinawa Prefectural Nanbu Medical Center and Children's MC
    Shimajiri-gun, Okinawa 901-1193, Japan
  • Kindai University Hospital
    Osakasayama-shi, Osaka 589-8511, Japan
  • Tokyo Metropolitan Hospital Organization Tokyo Metropolitan Children's Medical Center
    Fuchū, Tokyo 183-8561, Japan
  • Tokyo Metropolitan Bokutoh Hospital
    Sumida-ku, Tokyo 130-8575, Japan
  • Tokyo Metropolitan Ohtsuka Hospital
    Toshima-ku, Tokyo 170-8476, Japan
  • Kyushu University Hospital
    Fukuoka, 812-8582, Japan
  • Fukuoka University Hospital
    Fukuoka, 814-0180, Japan
  • Fukushima Medical University Hospital
    Fukushima, 960-1295, Japan
  • Hospital Kuala Lumpur
    Kuala Lumpur, 50586, Malaysia
  • Maxima Medisch Centrum, locatie Veldhoven
    Veldhoven, 5504 DB, Netherlands
  • Hospital Prof. Dr. Fernando Fonseca
    Amadora, Lisbon District 2720-276, Portugal
  • Unidade Local De Saúde De Lisboa Ocidental E.P.E.
    Lisbon, 1449-005, Portugal
  • Clinical Emergency County Hospital
    Cluj-Napoca, Cluj 400347, Romania
  • Spitalul Clinic de Obstretica si Ginecologie "Cuza Voda"
    Iași, 700038, Romania
  • FSAI NMRC IRTC "Eye Microsurgery", Kaluga's Branch
    Kaluga, 248007, Russia
  • FGBUZ "NPC of special children care n.a. Voino-Yaseneckogo"
    Moscow, 119620, Russia
  • City Children Hospital ?1
    Saint Petersburg, 198205, Russia
  • KK Women's and Children's Hospital
    Singapore, 229899, Singapore
  • Narodny ustav detskych chorob
    Bratislava, 833 41, Slovakia
  • Soon Chun Hyang University Cheonan Hospital
    Cheonan, Chungcheongnam-do 31151, South Korea
  • Asan Medical Center - Oncology Department
    Seoul, Seoul Teugbyeolsi 05505, South Korea
  • Hospital Universitario 12 de Octubre
    Madrid, 28041, Spain
  • Hospital la Paz - oftalmologia
    Madrid, 28046, Spain
  • Hospital Universitario Regional De Malaga - Oftalmologia
    Málaga, 29011, Spain
  • Sahlgrenska Universitetssjukhuset
    Gothenburg, 413 45, Sweden
  • Kaohsiung Medical University Chung-Ho Memorial Hospital
    Kaohsiung City, Kaohsiung 807377, Taiwan
  • Mackay Memorial Hospital
    Taipei, 104, Taiwan
  • Hacettepe Universitesi Tip Fakultesi
    Ankara, 6100, Turkey (Türkiye)
  • Gazi Universitesi Tip Fakultesi
    Ankara, 6560, Turkey (Türkiye)
  • Saglik Bilimleri Universitesi Antalya EA Hastanesi
    Antalya, 7100, Turkey (Türkiye)
  • Eskisehir Osmangazi Universitesi Tip Fakultesi
    Eskişehir, 26480, Turkey (Türkiye)
  • Adana Sehir Egitim ve Arastirma Hastanesi
    Yüreğir, 1370, Turkey (Türkiye)
  • Institute of Eye Diseases and Tissue Therapy named after V.I. Filatov, Consultative Polyclinic
    Odesa, 65061, Ukraine
  • Birmingham Womens Hospital
    Birmingham, B15 2TG, United Kingdom
08

References and documents

Publications

  • Stahl A, Nakanishi H, Lepore D, Wu WC, Azuma N, Jacas C, Vitti R, Athanikar A, Chu K, Iveli P, Zhao F, Leal S, Schlief S, Schmelter T, Miller T, Kofuncu E, Fielder A; FIREFLEYE next Study Group. Intravitreal Aflibercept vs Laser Therapy for Retinopathy of Prematurity: Two-Year Efficacy and Safety Outcomes in the Nonrandomized Controlled Trial FIREFLEYE next. JAMA Netw Open. 2024 Apr 1;7(4):e248383. doi: 10.1001/jamanetworkopen.2024.8383. PubMed 38687481 ↗

Individual participant data

Plan to share: No — Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2020 to primary completion in Sep 2025, 66 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 28, 2019
First posted
Jul 10, 2019
StartActual
Mar 18, 2020
Primary completionActual
Sep 19, 2025
CompletionActual
Sep 19, 2025
Last update
Oct 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04015180
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Jul 10, 2019
Start date
Mar 18, 2020
Primary completion
Sep 19, 2025
Completion
Sep 19, 2025
Last update
Oct 10, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aflibercept

Start the discussion